Trial ID or NCT#

NCT01526070

Status

NOT RECRUITING

Purpose

Over the last several years, the standard of care for wet macular degeneration has become treatment with intravitreal injections of ranibizumab (Lucentis, Genentech), administered as frequently as every 4 weeks. In contrast, clinical trials of a soluble VEGF receptor, Aflibercept/VEGF Trap-Eye (Eylea, Regeneron Pharmaceuticals) have demonstrated maintained anatomic and visual improvement with many fewer injections (typically monthly injections for 3 months, followed by every-other-month injections, and as few as 5 injections a year). The purpose of this study is to determine whether patients who have switched from ranibizumab to VEGF Trap-Eye have comparable results.

Official Title

Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Standard Therapy for Exudative Age-Related Macular Degeneration

Eligibility Criteria

Ages Eligible for Study: Older than 50 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Theodore Leng, MD, FACS
Retina specialist, Ophthalmologic surgeon, Cataract specialist, Ophthalmologist
Assistant Professor of Ophthalmology and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Theodore Leng, MD
(650) 723-6995